OPM Biosciences Launched New Biosimilar Platform
The company introduced a media optimization service to improve productivity and quality for biologic developers.
Updated on Oct. 1, 2026 in Biotech
Live Poll
Do you believe the growth in biosimilar development will make medical treatments more affordable?
OPM Biosciences has released its new Biosimilar Media Optimization Service and Sureness Biosimilar Platform. These tools are designed to help developers align quality attributes with reference biologics while increasing productivity for regulatory approval.
Why it matters
Patent expirations have triggered a surge in biosimilar development, forcing companies to find ways to balance high productivity with strict reference-product quality standards. This platform aims to address those technical hurdles during the manufacturing process.
The OPM-CHO cell culture media platform has supported more than 390 molecules, achieving an average titer improvement of 96% across 35 evaluations. Internal studies show that this media maintains lot-to-lot variability below 5%.
The players
OPM Biosciences
This biotechnology company specializes in developing cell culture media platforms and manufacturing services for the pharmaceutical industry.
The details
The service uses molecule-specific media development to tune critical quality attributes toward reference-product profiles. It integrates media development with contract manufacturing capabilities to streamline regulatory submissions in the U.S. and China.
Timeline
October 1, 2026: OPM Biosciences launched the new biosimilar platforms and services.
The Tech Race
The development of optimized media platforms mirrors the broader race to streamline complex manufacturing processes as biologic patent expirations expand the biosimilar market. This shift replaces traditional development methods with integrated frameworks that accelerate the path to regulatory approval.
Developers utilizing this platform can expect faster regulatory submission timelines and improved alignment with reference biologic quality standards. These efficiencies could potentially reduce development hurdles for complex therapeutics aiming for market entry in the U.S. and China.
The takeaway
The introduction of specialized optimization services reflects a growing industry focus on maximizing production titers while meeting rigid clinical benchmarks. Companies that successfully bridge the gap between media performance and regulatory compliance stand to capture more share in the maturing biosimilar sector.
Further reading
For more on the current industry landscape, explore our Biotech section.
Source note: This article includes information reported by Selectscience.
Live Poll
Do you believe the growth in biosimilar development will make medical treatments more affordable?
